DOCSLIB.ORG

Llllllllllllllilllllllllllllllllllllllllllllllllllllllllllll

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Llllllllllllllilllllllllllllllllllllllllllllllllllllllllllll llllllllllllllIllllllllllllllllllllllllllllllllllllllllllllllllIlllllllllll USOO5563140A United States Patent [191 [11] Patent Number: 5,563,140 Ehrenberger et al. [45] Date of Patent: Oct. 8, 1996 [54] USE OF 1-(AMINOALKYL)-3-(BENZYL) Kessler et al, “Quinoxaline derivatives are high-affinity QUINOXALINE-Z-ONE DERIVATIVES FOR antagonists of the NMDA receptor-associated glycine THE PREPARATION OF sites”, Brain Research, vol. 489 (1989), pp. 377-382. NEUROPROTECTIVE COMPOSITIONS A. Mule et al, ‘"Terz-aumrinoalcl?lderivati di chinossalinoni ad attivita analgesica”, Il Farmaco Edizione Scienti?ca, vol. [75] Inventors: Klaus Ehrenberger, Vienna, Austria; 43, No. 7-8 (Aug. 1988), pp. 613—618. Dominik Felix, Zurich, Switzerland Subsidia Medica, 22, 3, pp. 78-85 (1970). Koppi et a1, “Calcium—Chaunel-Blocking Agent in the [73] Assignee: Phafag Aktiengesellschaft, Schaan, Treatment of Acute Alcohol Withdrawal-Caroverine ver Liechtenstein sus Meprobamate in a Randomized Double—Blind Study”, Neuropsychobiology, 17, pp. 49-52 (1987). [21] Appl. No.: 975,328 Presslich et al, “Oesterreichische Apothekerzeitung”, 38/39, Filed: Nov. 16, 1992 p. 757 (1984). [22] Honore et al, “Quinoxalinediones: Potent Competitive [30] Foreign Application Priority Data Non-NMDA Glutamate Receptor Antagonists”, Science, 241, pp. 701-703 (1988). Nov. 15, 1991 [EP] European Pat. 0a. ............. .. 91119501 Merck Index, 11th Ed., 1989, #1864. [51] Int. Cl.6 ...................... .. A61K 31/55; A61K 31/495; CA 99:3359, Ishida et al., 1983. A61K 31/50 Kaplan Clinical Hypenension p. 235 1986. [52] US. Cl. ........................................... .. 514/249; 514/212 Merck Manual p. 1308-1309; 1324-1327 1982. [58] Field of Search ................................... .. 514/410, 212, Primary Examiner—Kimberly Jordan 514/249 Attorney, Agent, or Firm-—Millen, White, Zelano, & Brani gan, RC. [56] References Cited U.S. PATENT DOCUMENTS [571 ABSTRACT 5,037,848 8/1991 Olney .................................... .. 514/428 Compounds of the formula FOREIGN PATENT DOCUMENTS R3 N 0032564 7/ 1981 European Pat. O?”. 228204 7/ 1963 Germany . WO90/ 15606 12/1990 WIPO . (I N O OTHER PUBLICATIONS | R1 “Studies of experimental cerebral artery dilatation (with (CH) N/ caroverin fumarate”, Neurological Surgery, Abstracts of the 7th lntemational Congress of Neurological Surgery, Munich, Germany (Jul. 12-18, 1981), Supplement to Neu wherein rochirugia, Abstract No. 8.3.1, vol. 0, No. SU, p. 332, J. O. R1 and R2 are each independently hydrogen, methyl, Widauer. ethyl, propyl, butyl or R1 and R2 are together . B. Meldrum, “Excitatory amino acid neurotoxicity and cycloalkyl; neurodegenerative disease”, Trends in Pharmacological Sci~ R3 is methoxy, ethoxy, hydroxy, hydrogen, C1_4 alkyl, ences, vol. 11, No. 9 (Sep. 1990), pp. 379-387. halogen; M. Ishida et a1, “Reduction of glutamate responses at the cray?sh neuromuscular junction”, Brain Research, vol. 266, n=l, 2 or 3; No. 1 (Apr. 25, 1983), pp. 174-177. or any pharmaceutically acceptable salts thereof are useful Y. Kudo et a1, “Eifects of caroveiine and diltiazem on for the preparation of neuroprotective pharmaceutical com synaptic responses, L—glutamate—induced depolarization positions, for the prevention or treatment of glutamate and potassium e?lux in the frog spinal cord”, British Journal induced and glutamate receptor mediated neurotoxicity and of Pharmacology, vol. 83, No. 3 (Nov. 1984), pp. 813—-820. functional disturbances of the central nervous system. H. Shinozaki, “Pharmacology of the Glutamate Receptor”, Progress in Technology, vol. 30 (1988), pp. 399—435. 16 Claims, 3 Drawing Sheets US. Patent Oct. 8, 1996 Sheet 1 of 3 5,563,140 IO m Of .__I'_"_‘1 Glu15 FIG. lu 1mV L20 msec DURING Glu 15 U.S. Patent - 0a. 8, 1996 Sheet 2 of3 5,563,140 1min 1 .... 4 "‘ 0 r0 * LUg (\l E 4 g 5?. 4{I LL. 0 Glu15 US. Patent Oct. 8, 1996 Sheet 3 of 3 5,563,140 1min CAROVERINE3o FlG.3 ACh6O Glu60 5,563,140 1 2 USE OF 1-(AMINOALKYL)-3-(BENZYL) the use of Caroverine in treatment of acute alcohol with QUINOXALINE-Z-ONE DERIVATIVES FOR drawal symptoms. Koppi et al were inspired by Presslich THE PREPARATION OF NEUROPROTECTIVE COMPOSITIONS and Brainin (Oesterreichische Apothekerzeitung 38/39, p. 757 (1984)) who has tested Caroverine during alkaloid The present invention relates to the novel use of l-(ami withdrawal. noalkyl)-3-(benzyl)-quinoxaline-2-one derivatives and In contrast to the cited publications the present invention pharmaceutically acceptable salts thereof for the preparation is based on the surprising discovery of 1-(aminoalkyl)-3 of neuroprotective pharmaceutical compositions. (benzyl)-quinoxaline-2-one derivatives as potent, selective Compounds of the formula 10 and reversible glutamate receptor antagonists in the excita tory neurotransmission in the central nervous system. Glutamate is the most abundant and important excitatory neurotransmitter in the central nervous system (Brien Mel drum in Emerging Strategies in Neuroprotection, edited by P. J. Marangos and Harbans Lal, Birkhauser Boston, 1992, chapter 7). In the central nervous system, glutamate func tions to promote rapid neurotransmitter depolarization by opening membrane channels chemically (in contrast to the wherein voltage-gated inhibition of CaH-in?ux in smooth muscle R1 and R2 are each independently hydrogen, methyl, cells) which permit diffusion of sodium and calcium ions. ethyl, propyl, butyl, or R1 and R2 are together cycloalkyl (e.g., of 3-7 C-atoms); These fast effects are mediated by different glutamate sensitive receptor types which act as a speci?c “central R3 is methoxy, ethoxy, hydroxy, hydrogen, C1-C4 alkyl, 25 halogen (e.g., F, Cl, Br or 1); key/lock system” and permit excitation of the subsequent nerve cell. n=1, 2 or 3, hereinafter referred to as l-(aminoalkyl)-3-(benzyl)-qui The glutamate receptors are extremely sensitive to a wide noxaline-Z-one derivatives, have been known for more than range of external damage (noxae), such as injuries, oxygen three decades (OE-A-228 204). l-(Aminoalkyl)-3—substi 30 de?ciency, metabolic disturbances, aging processes, etc., tuted-quinoxaline-2-one derivatives which have in the 3-po and, under these conditions, lead to a speci?c kind of sition a benzyl residue show a papaverine-like activity. overstimulation of the subsequent nerve cell. ( 1 -Diethyl amino ethyl)-3 -(p-methoxybenzyl)- 1 ,2-dihydro Under the conditions of an excessive stimulation of the quinoxaline-Z-one with the International Non-Proprietary receptors, the physiological transmitter glutamate exerts a name (INN) Caroverine, a member of the above class, was 35 discovered to be a powerful spasmolyticum, which is used neurotoxic action (Rothman et al in Trends Neurosci. 10 mainly in the gastrointestinal region. The e?icacy of (1987), pp. 299-302). This excitotoxicity is mediated by the Caroverine is attributed to its calcium-blocking capacities receptors N-methyl-D-aspartate (NMDA) as well as by the whereby it blocks the calcium mediated activation of myo two non-NMDA subtypes, quisqualate and kainate (Frand ?brillar ATPase, predominantly in smooth muscles. sen et al, J. Neurochem. 53 (1990), pp. 297-299), whereby In EP-A 032 564 the use of Caroverine-fumarate for the Ca is involved in the etiology of the glutamate-induced cell inhibition of the aggregation of platelets in blood, increase of the arterial circulation, treating of ischemic heart diseases, damage which can ?nally result in the death of the affected angina pectoris, etc. was described. In addition, speci?c neurons. (Choi, Trends Neurosc, 11 (1988), pp. 465-469). Caroverine salts had i.a. a positive e?ect on the cerebral 45 This glutamate receptor-linked neurotoxicity has been impli blood circulation. It was also found that Caroverine is a cated in pathological conditions like ischemia, hypoglyce speci?c Ca-antagonist (EP-A 032 564; page 18): The cardiac mia, anoxia, trauma and several severe neurodegenerative muscles and the smooth muscles contract under the in?u disorders (Meldrum et al, Trends pharmacol. Sci. 11(1990), ence of calcium ions. The Ca-ions enter the muscle cells through speci?c calcium channels and induce the contract pp. 379-387) as well as in neuronal death in aging. In vitro ing process from the inner'cell. The calcium channels can be and in vivo, glutamate receptor antagonists, as neuroprotec opened either by local voltage changes (voltage gated ionic tive agents, can prevent these pathological conditions. channels), tissue hormones or by the transmitter adrenalin. It Therefore, there is a great interest in the development of has been found that Caroverine is capable of inhibiting 50% new drugs that might selectively block the NMDA and of the flux of Ca-ions into the cell via “voltage gated 55 non-NMDA receptors without in?uencing other receptors channels” opened by electrical stimulation (EP-A 032 564; since such drugs could be used as neuroprotective pharma page 18). The in?uence of calcium on the chemical calcium ceuticals. Applications of these pharmaceuticals could be the channels has not been examined. treatment of glutamate-induced and glutamate-receptor-me Widauer studied the effect of Caroverine fumarate on cerebral artery dilatation (Neurological Surger, suppl. to diated neurotoxic dysfunctions such as functional distur Neurochirurgia, 1981, p. 332, abstract no. 8.3.1). He, too, bances of the inner ear, like tinnitus and impaired hearing, attributed the e?cect of Caroverine to its role as Ca-antago and of the retina, (POSOtraumatic lesions, and degenerative nist. processes
Load more

Recommended publications
  • Sleep-Dependent Declarative Memory Consolidation&Mdash
    Neuropsychopharmacology (2013) 38, 2688–2697 & 2013 American College of Neuropsychopharmacology. All rights reserved 0893-133X/13 www.neuropsychopharmacology.org Sleep-Dependent Declarative Memory Consolidation— Unaffected after Blocking NMDA or AMPA Receptors but Enhanced by NMDA Coagonist D-Cycloserine ,1,2 2 3 ,1,4 Gordon B Feld* , Tanja Lange , Steffen Gais and Jan Born* 1Institute of Medical Psychology and Behavioral Neurobiology, University of Tuebingen, Tuebingen, Germany; 2Department of Neuroendocrinology, University of Luebeck, Luebeck, Germany; 3Institute of Psychology, Ludwig-Maximilian University, Munich, Germany; 4 Center for Integrative Neuroscience, University of Tuebingen, Tuebingen, Germany Sleep has a pivotal role in the consolidation of declarative memory. The coordinated neuronal replay of information encoded before sleep has been identified as a key process. It is assumed that the repeated reactivation of firing patterns in glutamatergic neuron assemblies translates into plastic synaptic changes underlying the formation of longer-term neuronal representations. Here, we tested the effects of blocking and enhancing glutamatergic neurotransmission during sleep on declarative memory consolidation in humans. We conducted three placebo-controlled, crossover, double-blind studies in which participants learned a word-pair association task. Afterwards, they slept in a sleep laboratory and received glutamatergic modulators. Our first two studies aimed at impairing consolidation by administering the NMDA receptor blocker ketamine and the AMPA receptor blocker caroverine during retention sleep, which, paradoxically, remained unsuccessful, inasmuch as declarative memory performance was unaffected by the treatment. However, in the third study, administration of the NMDA receptor coagonist D-cycloserine (DCS) during retention sleep facilitated consolidation of declarative memory (word pairs) but not consolidation of a procedural control task (finger sequence tapping).
    [Show full text]
  • )&F1y3x PHARMACEUTICAL APPENDIX to THE
    )&f1y3X PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE )&f1y3X PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 3 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABAMECTIN 65195-55-3 ACTODIGIN 36983-69-4 ABANOQUIL 90402-40-7 ADAFENOXATE 82168-26-1 ABCIXIMAB 143653-53-6 ADAMEXINE 54785-02-3 ABECARNIL 111841-85-1 ADAPALENE 106685-40-9 ABITESARTAN 137882-98-5 ADAPROLOL 101479-70-3 ABLUKAST 96566-25-5 ADATANSERIN 127266-56-2 ABUNIDAZOLE 91017-58-2 ADEFOVIR 106941-25-7 ACADESINE 2627-69-2 ADELMIDROL 1675-66-7 ACAMPROSATE 77337-76-9 ADEMETIONINE 17176-17-9 ACAPRAZINE 55485-20-6 ADENOSINE PHOSPHATE 61-19-8 ACARBOSE 56180-94-0 ADIBENDAN 100510-33-6 ACEBROCHOL 514-50-1 ADICILLIN 525-94-0 ACEBURIC ACID 26976-72-7 ADIMOLOL 78459-19-5 ACEBUTOLOL 37517-30-9 ADINAZOLAM 37115-32-5 ACECAINIDE 32795-44-1 ADIPHENINE 64-95-9 ACECARBROMAL 77-66-7 ADIPIODONE 606-17-7 ACECLIDINE 827-61-2 ADITEREN 56066-19-4 ACECLOFENAC 89796-99-6 ADITOPRIM 56066-63-8 ACEDAPSONE 77-46-3 ADOSOPINE 88124-26-9 ACEDIASULFONE SODIUM 127-60-6 ADOZELESIN 110314-48-2 ACEDOBEN 556-08-1 ADRAFINIL 63547-13-7 ACEFLURANOL 80595-73-9 ADRENALONE
    [Show full text]
  • PHARMACEUTICAL APPENDIX to the TARIFF SCHEDULE 2 Table 1
    Harmonized Tariff Schedule of the United States (2020) Revision 19 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2020) Revision 19 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names INN which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service CAS registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known.
    [Show full text]
  • Tinnitus: Causes and Treatment Science Notes
    Tinnitus: Causes and Treatment Science Notes created dec. 31, 2007; updated oct 18, 2012 Tinnitus: Causes and Treatment The high-pitched sound at the beginning of the TV show Outer Limits is very similar to the sounds heard by many tinnitus sufferers. n the United States, about 10-15% of the population suffer from tinnitus, known colloquially as "ringing in the ears." Tinnitus is not just unwanted noise; it is extremely unpleasant and often interferes with enjoyment of music. It can make verbal communication impossible and can cause depression. Conventional medical thinking used to be that tinnitus arises from injury to cells in the inner ear or the vestibulocochlear nerve (also known as the acoustic nerve, auditory nerve, or cranial nerve VIII), and is therefore difficult or impossible to treat. However, it is now recognized that this is not always the case. Researchers now realize that rewiring of an area in the brainstem called the dorsal cochlear nucleus plays an important role in tinnitus. This new understanding of its causes may result in new treatments for many patients. Indeed, recent results based on this theory are already leading to effective forms of treatment in some patients. However, many physicians are unaware of the causes of tinnitus and the problems endured by tinnitus sufferers, and they will often tell the patient that the problem is imaginary or unimportant. This often causes the patient to abandon attempts to get treatment. This is unfortunate, because recent research suggests that tinnitus is easier to cure when treatment is given early. In this article, I will discuss what is known about tinnitus and what tinnitus sufferers can do about their affliction.
    [Show full text]
  • Partial Agreement in the Social and Public Health Field
    COUNCIL OF EUROPE COMMITTEE OF MINISTERS (PARTIAL AGREEMENT IN THE SOCIAL AND PUBLIC HEALTH FIELD) RESOLUTION AP (88) 2 ON THE CLASSIFICATION OF MEDICINES WHICH ARE OBTAINABLE ONLY ON MEDICAL PRESCRIPTION (Adopted by the Committee of Ministers on 22 September 1988 at the 419th meeting of the Ministers' Deputies, and superseding Resolution AP (82) 2) AND APPENDIX I Alphabetical list of medicines adopted by the Public Health Committee (Partial Agreement) updated to 1 July 1988 APPENDIX II Pharmaco-therapeutic classification of medicines appearing in the alphabetical list in Appendix I updated to 1 July 1988 RESOLUTION AP (88) 2 ON THE CLASSIFICATION OF MEDICINES WHICH ARE OBTAINABLE ONLY ON MEDICAL PRESCRIPTION (superseding Resolution AP (82) 2) (Adopted by the Committee of Ministers on 22 September 1988 at the 419th meeting of the Ministers' Deputies) The Representatives on the Committee of Ministers of Belgium, France, the Federal Republic of Germany, Italy, Luxembourg, the Netherlands and the United Kingdom of Great Britain and Northern Ireland, these states being parties to the Partial Agreement in the social and public health field, and the Representatives of Austria, Denmark, Ireland, Spain and Switzerland, states which have participated in the public health activities carried out within the above-mentioned Partial Agreement since 1 October 1974, 2 April 1968, 23 September 1969, 21 April 1988 and 5 May 1964, respectively, Considering that the aim of the Council of Europe is to achieve greater unity between its members and that this
    [Show full text]
  • Specific Changes in Sleep Oscillations After Blocking Human Metabotropic Glutamate
    bioRxiv preprint doi: https://doi.org/10.1101/2020.07.24.219865; this version posted July 26, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY 4.0 International license. Specific changes in sleep oscillations after blocking human metabotropic glutamate receptor 5 in the absence of altered memory function Gordon B. Feld*1,2, Til Ole Bergmann*2,3,5, Marjan Alizadeh-Asfestani2, Viola Stuke2, Jan- Philipp Wriede2, Surjo Soekadar2, Jan Born2,4 1 Clinical Psychology, Central Institute of Mental Health, University of Heidelberg, Mannheim, Germany 2 Institute of Medical Psychology and Behavioral Neurobiology, University of Tübingen, Tübingen, Germany 3 Department of Neurology & Stroke, and Hertie Institute for Clinical Brain Research, University of Tübingen, Tübingen, Germany 4 Centre for Integrative Neuroscience, University of Tübingen, Tübingen, Germany 5 Leibniz Institute for Resilience Research (LIR), Mainz, Germany * these authors contributed equally Correspondence: Gordon Feld, Email: [email protected], Address: Central Institute for Mental Health, J5, 68159 Mannheim, Germany, Tel. +49 621 1703 6540, Fax +49 621 1703 6505. 1 bioRxiv preprint doi: https://doi.org/10.1101/2020.07.24.219865; this version posted July 26, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY 4.0 International license. Abstract Sleep consolidates declarative memory by the repeated replay of neuronal traces encoded during prior wakefulness.
    [Show full text]
  • Randomised Controlled Clinical Study to Evaluate the Efficacy of IV
    International Journal of Otorhinolaryngology and Head and Neck Surgery Dhulipalla S et al. Int J Otorhinolaryngol Head Neck Surg. 2021 May;7(5):803-808 http://www.ijorl.com pISSN 2454-5929 | eISSN 2454-5937 DOI: https://dx.doi.org/10.18203/issn.2454-5929.ijohns20211572 Original Research Article Randomised controlled clinical study to evaluate the efficacy of IV injection of caroverine and intratympanic steroid injection in the treatment of cochlear synaptic tinnitus with sensorineural hearing loss Sharmila Dhulipalla*, Radhika Sodadasu Department of Otorhinolaryngology, Katuri Medical College and Hospital, Guntur, Andhra Pradesh, India Received: 18 February 2021 Revised: 04 April 2021 Accepted: 07 April 2021 *Correspondence: Dr. Sharmila Dhulipalla, E-mail: [email protected] Copyright: © the author(s), publisher and licensee Medip Academy. This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial License, which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. ABSTRACT Background: Cochlear synaptic tinnitus with sensorineural hearing loss (SNHL) is the most common type of subjective tinnitus. Many therapies were tried, but nothing is well proven to cure this. Hence, our present study aims to assess the efficacy of intravenous (IV) injection of caroverine and intratympanic steroid injection in treatment of cochlear synaptic tinnitus with SNHL. Methods: This study was carried out at the ear, nose and throat (ENT) department with 60 patients (22 male, 38 female) between the ages of 20 and 70 who had idiopathic tinnitus. Patients who met inclusion criteria were randomized by simple randomization and divided into two groups.
    [Show full text]
  • THÈSE Pour Le DIPLÔME D'état DE DOCTEUR EN PHARMACIE Par
    UNIVERSITÉ DE NANTES FACULTÉ DE PHARMACIE ----------------------------------------------------------------------------- ANNEE 2012 N° 048 THÈSE pour le DIPLÔME D'ÉTAT DE DOCTEUR EN PHARMACIE par Élodie BOSSIS ------------------------------ Présentée et soutenue publiquement le 10 SEPTEMBRE 2012 PRISE EN CHARGE DES ACOUPHENES, QUEL ROLE POUR LE PHARMACIEN D'OFFICINE? Président : M. Christos ROUSSAKIS, Professeur de biologie cellulaire et de génétique moléculaire Membres du jury : Mme Pascale ROUSSEAU, Maître de Conférences associé à mi-temps. Service de pharmacologie et pharmacocinétique Mme Sophie TOUFFLIN-RIOLI, Pharmacien TABLE DES MATIERES PAGE INTRODUCTION ................................................................................................ 5 CHAPITRE I : LE SON ET L’AUDITION ................................................................ 6 CHAPITRE II : PHYSIOPATHOLOGIE ................................................................ 15 2.1 Les acouphènes objectifs ....................................................................... 15 2.1.1 Origine vasculaire ....................................................................................... 15 2.1.2 Origine mécanique ...................................................................................... 16 2.2 Les acouphènes subjectifs ..................................................................... 16 2.2.1 Traumatisme sonore ................................................................................... 17 2.2.2 Barotraumatisme .......................................................................................
    [Show full text]
  • Pharmaceutical Appendix to the Tariff Schedule 2
    Harmonized Tariff Schedule of the United States (2007) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2007) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. ABACAVIR 136470-78-5 ACIDUM LIDADRONICUM 63132-38-7 ABAFUNGIN 129639-79-8 ACIDUM SALCAPROZICUM 183990-46-7 ABAMECTIN 65195-55-3 ACIDUM SALCLOBUZICUM 387825-03-8 ABANOQUIL 90402-40-7 ACIFRAN 72420-38-3 ABAPERIDONUM 183849-43-6 ACIPIMOX 51037-30-0 ABARELIX 183552-38-7 ACITAZANOLAST 114607-46-4 ABATACEPTUM 332348-12-6 ACITEMATE 101197-99-3 ABCIXIMAB 143653-53-6 ACITRETIN 55079-83-9 ABECARNIL 111841-85-1 ACIVICIN 42228-92-2 ABETIMUSUM 167362-48-3 ACLANTATE 39633-62-0 ABIRATERONE 154229-19-3 ACLARUBICIN 57576-44-0 ABITESARTAN 137882-98-5 ACLATONIUM NAPADISILATE 55077-30-0 ABLUKAST 96566-25-5 ACODAZOLE 79152-85-5 ABRINEURINUM 178535-93-8 ACOLBIFENUM 182167-02-8 ABUNIDAZOLE 91017-58-2 ACONIAZIDE 13410-86-1 ACADESINE 2627-69-2 ACOTIAMIDUM 185106-16-5 ACAMPROSATE 77337-76-9
    [Show full text]
  • Marrakesh Agreement Establishing the World Trade Organization
    No. 31874 Multilateral Marrakesh Agreement establishing the World Trade Organ ization (with final act, annexes and protocol). Concluded at Marrakesh on 15 April 1994 Authentic texts: English, French and Spanish. Registered by the Director-General of the World Trade Organization, acting on behalf of the Parties, on 1 June 1995. Multilat ral Accord de Marrakech instituant l©Organisation mondiale du commerce (avec acte final, annexes et protocole). Conclu Marrakech le 15 avril 1994 Textes authentiques : anglais, français et espagnol. Enregistré par le Directeur général de l'Organisation mondiale du com merce, agissant au nom des Parties, le 1er juin 1995. Vol. 1867, 1-31874 4_________United Nations — Treaty Series • Nations Unies — Recueil des Traités 1995 Table of contents Table des matières Indice [Volume 1867] FINAL ACT EMBODYING THE RESULTS OF THE URUGUAY ROUND OF MULTILATERAL TRADE NEGOTIATIONS ACTE FINAL REPRENANT LES RESULTATS DES NEGOCIATIONS COMMERCIALES MULTILATERALES DU CYCLE D©URUGUAY ACTA FINAL EN QUE SE INCORPOR N LOS RESULTADOS DE LA RONDA URUGUAY DE NEGOCIACIONES COMERCIALES MULTILATERALES SIGNATURES - SIGNATURES - FIRMAS MINISTERIAL DECISIONS, DECLARATIONS AND UNDERSTANDING DECISIONS, DECLARATIONS ET MEMORANDUM D©ACCORD MINISTERIELS DECISIONES, DECLARACIONES Y ENTEND MIENTO MINISTERIALES MARRAKESH AGREEMENT ESTABLISHING THE WORLD TRADE ORGANIZATION ACCORD DE MARRAKECH INSTITUANT L©ORGANISATION MONDIALE DU COMMERCE ACUERDO DE MARRAKECH POR EL QUE SE ESTABLECE LA ORGANIZACI N MUND1AL DEL COMERCIO ANNEX 1 ANNEXE 1 ANEXO 1 ANNEX
    [Show full text]
  • Ep 2932971 A1
    (19) TZZ ¥ __T (11) EP 2 932 971 A1 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51) Int Cl.: 21.10.2015 Bulletin 2015/43 A61K 31/54 (2006.01) A61K 31/445 (2006.01) A61K 9/08 (2006.01) A61K 9/51 (2006.01) (2006.01) (21) Application number: 15000954.6 A61L 31/00 (22) Date of filing: 06.03.2006 (84) Designated Contracting States: • MCCORMACK, Stephen, Joseph AT BE BG CH CY CZ DE DK EE ES FI FR GB GR Claremont, CA 91711 (US) HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI • SCHLOSS, John, Vinton SK TR Valencia, CA 91350 (US) • NAGY, Anna Imola (30) Priority: 04.03.2005 US 658207 P Saugus, CA 91350 (US) • PANANEN, Jacob, E. (62) Document number(s) of the earlier application(s) in 306 Los Angeles, CA 90042 (US) accordance with Art. 76 EPC: 06736872.0 / 1 861 104 (74) Representative: Ali, Suleman et al Avidity IP Limited (71) Applicant: Otonomy, Inc. Broers Building, Hauser Forum San Diego, CA 92121 (US) 21 JJ Thomson Avenue Cambridge CB3 0FA (GB) (72) Inventors: • LOBL, Thomas, Jay Remarks: Valencia, This application was filed on 09-04-2015 as a CA 91355-1995 (US) divisional application to the application mentioned under INID code 62. (54) KETAMINE FORMULATIONS (57) Formulations of ketamine for administration to the inner or middle ear. EP 2 932 971 A1 Printed by Jouve, 75001 PARIS (FR) EP 2 932 971 A1 Description [0001] This application claims the benefit of Serial No. 60/658,207 filed March 4, 2005.
    [Show full text]
  • Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DIX to the HTSUS—Continued
    20558 Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DEPARMENT OF THE TREASURY Services, U.S. Customs Service, 1301 TABLE 1.ÐPHARMACEUTICAL APPEN- Constitution Avenue NW, Washington, DIX TO THE HTSUSÐContinued Customs Service D.C. 20229 at (202) 927±1060. CAS No. Pharmaceutical [T.D. 95±33] Dated: April 14, 1995. 52±78±8 ..................... NORETHANDROLONE. A. W. Tennant, 52±86±8 ..................... HALOPERIDOL. Pharmaceutical Tables 1 and 3 of the Director, Office of Laboratories and Scientific 52±88±0 ..................... ATROPINE METHONITRATE. HTSUS 52±90±4 ..................... CYSTEINE. Services. 53±03±2 ..................... PREDNISONE. 53±06±5 ..................... CORTISONE. AGENCY: Customs Service, Department TABLE 1.ÐPHARMACEUTICAL 53±10±1 ..................... HYDROXYDIONE SODIUM SUCCI- of the Treasury. NATE. APPENDIX TO THE HTSUS 53±16±7 ..................... ESTRONE. ACTION: Listing of the products found in 53±18±9 ..................... BIETASERPINE. Table 1 and Table 3 of the CAS No. Pharmaceutical 53±19±0 ..................... MITOTANE. 53±31±6 ..................... MEDIBAZINE. Pharmaceutical Appendix to the N/A ............................. ACTAGARDIN. 53±33±8 ..................... PARAMETHASONE. Harmonized Tariff Schedule of the N/A ............................. ARDACIN. 53±34±9 ..................... FLUPREDNISOLONE. N/A ............................. BICIROMAB. 53±39±4 ..................... OXANDROLONE. United States of America in Chemical N/A ............................. CELUCLORAL. 53±43±0
    [Show full text]